- Motley Fool•6 hours ago
George Soros' namesake fund dumped its entire holdings in the iShares Nasdaq Biotechnology Index Fund, Gilead Sciences, and Novavax.
- Benzinga•19 hours ago
Biotech is one of the sectors where M&A activities never stop, as the potential for growth and development is immense. After the termination of a $160 billion merger with Allergan plc Ordinary Shares (NYSE: ...
- TheStreet.com•2 days ago
Citigroup analysts say IMS Health (IMS) data show that Gilead's (GILD) hepatitis-C drug sales may be below forecasts.
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||79.63 x 700|
|Ask||79.77 x 200|
|Day's Range||79.27 - 80.33|
|52wk Range||77.92 - 113.31|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||7.00|
|Avg Vol (3m)||10,159,655|
|Dividend & Yield||1.88 (2.36%)|